About Boehringer Ingelheim
Boehringer Ingelheim is a company based in Ingelheim Am Rhein (Germany) founded in 1885. Boehringer Ingelheim has completed 16 acquisitions, including AMAL Therapeutics, AbeXXa Biologics and Actimis.
- Headquarter Ingelheim Am Rhein, Germany
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
$268.81 K (USD), Grant
Sep 01, 2022
- Investors
-
Employee Count
Not available
-
Investments & Acquisitions
AMAL Therapeutics
& 15 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Boehringer Ingelheim
Unlock access to complete
Software Development Team
63 people
Leadership Team
54 people
Finance and Accounting
26 people
Sales and Marketing
18 people
Head Team
17 people
Senior Team
12 people
Product Management Team
11 people
Creative and Marketing Team
6 people
Unlock access to complete
Funding Insights of Boehringer Ingelheim
Investors in Boehringer Ingelheim
Boehringer Ingelheim has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked |
Investor details for Boehringer Ingelheim
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Boehringer Ingelheim
Boehringer Ingelheim has strategically engaged in corporate development activities, having acquired 16 companies. Notable acquisitions include AMAL Therapeutics, AbeXXa Biologics and Actimis.
Investment portfolio details for Boehringer Ingelheim
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Technology for immunotherapy drug discovery is developed via high-throughput screening.
|
Locked | Locked | 2019 | Locked | |
|
Provider of veterinary healthcare products development & marketing services
|
Locked | Locked | 2017 | Locked | |
|
Cytokines for cancer treatment are developed with tumor-site activation.
|
Locked | Locked | 2017 | Locked |
Complete acquisition details for Boehringer Ingelheim
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Boehringer Ingelheim
Detailed financials for Boehringer Ingelheim
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Boehringer Ingelheim Comparisons
Peer comparison for Boehringer Ingelheim
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Boehringer Ingelheim
Detailed competitors of Boehringer Ingelheim
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Boehringer Ingelheim
Complete news archive for Boehringer Ingelheim
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Boehringer Ingelheim
Boehringer Ingelheim was founded in 1885 and raised its 1st funding round 131 years after it was founded.
Boehringer Ingelheim is headquartered in Ingelheim Am Rhein, Germany. It is registered at Ingelheim Am Rhein, Rheinland-pfalz, Germany.
Jean-Michel Boers is the current CEO of Boehringer Ingelheim.
Boehringer Ingelheim was founded in 1885 as a pharmaceutical entity focused on generic drugs and clinical research services. Operations are centered in the healthcare sector, with emphasis on drug development and research support. Leadership includes Co-CEO Jean-Michel Boers, CEO Hubertus Von Baumbach, and Managing Director Fei Shen. The company maintains a presence through its domain boehringer-ingelheim.com, though specific location details are not specified.
Boehringer Ingelheim has made 16 acquisitions, including AMAL Therapeutics, AbeXXa Biologics, and Actimis.
Boehringer Ingelheim has 1 investor. Key investors include European Union.